Ami Organics Ltd. IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 4,669,143 (50%) | — | ₹28,482 Cr |
| NII (HNI) | — | 1,400,744 (15%) | — | ₹8,545 Cr |
| Retail | — | 3,268,401 (35%) | — | ₹19,937 Cr |
| Σ Total | — | 9,338,288 (100%) | — | ₹569,636 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 24 | ₹14,640 |
| Retail (Max) | 13 | 312 | ₹190,320 |
| S-HNI (Min) | 14 | 336 | ₹204,960 |
| B-HNI (Min) | 67 | 1,608 | ₹980,880 |
Financial Statements Amount in Crore
| Metric | 31-Mar-21 | 31-Mar-20 | 31-Mar-19 |
|---|---|---|---|
| Revenue | 342 | 242 | 239 |
| Profit After Tax | 54 | 27 | 23 |
| Total Assets | 413 | 232 | 213 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- 1 Repayment/prepayment of certain financial facilities availed by the Company – 140.00
- 2 Funding working capital requirements of the Company; and – 90.00
- 3 General corporate purposes – 45.98
Company Overview
Incorporated in 2004, Ami Organics Limited is one of the leading research and development driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical ingredients (API) for New Chemical Entities, and material for agrochemicals and fine chemicals.
The company has developed over 450 pharma intermediates across 17 key therapeutic areas i.e. anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. It supplies its products to more than 150 customers (including international customers) directly in India and in 25 countries overseas i.e. Europe, USA, China, Israel, Japan, Latin America, etc. Laurus Labs, Cadila Healthcare, Cipla Ltd are some of the domestic customers whereas Organike s.r.l.a. Socio Unico, Fermion Oly, Medichem S.A. and Midas Pharma GmbH are some of the international customers.
The company has three manufacturing facilities in Gujarat situated at Sachin, Ankleshwar & Jhagadia, with an aggregate installed capacity of 6,060 MTPA.
Competitive strengths:
- One of the leading manufacturers of certain Pharma Intermediates i.e. Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.
- Strong and diversified product portfolio with 450+ Pharma Intermediates across 17 therapeutic areas.
- Extensive geographical presence and diversified customer base.
- Strong R&D, sales and marketing capabilities
- Consistent financial performance track record.